Indications
Administration/AbsorptionDosage
DistributionMechanism- tissue plasminogen activator (tPA)
- produced by recombinant DNA technology using an established mammalian cell line
- derived from native t-PA by modifications at three sites of the protein
structure
- higher fibrin specificity and greater resistance to inactivation by its
endogenous inhibitor (PAI-1) compared to native t-PA.
ExcretionSide effectsInteractions
Contraindications
|
|
